| Overview of Clinical Research | <div class=”section-content-item” style=”font-size: 16px; box-sizing: inherit; max-width: 100%; color: rgb(33, 33, 33); font-family: -apple-system, system-ui, "Segoe UI", Roboto, Oxygen, Oxygen-Sans, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", "Source Sans Pro", sans-serif; font-variant-ligatures: normal; orphans: 2; widows: 2;”>
<p style=”box-sizing: inherit; word-break: break-word; overflow-wrap: break-word; margin: 0px; padding-top: 0.25em; padding-left: 0px; line-height: 1.5;”>
<span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Tasimelteon is currently the only drug available for the treatment of <span style=”font-variant-ligatures: normal;”>Non-24-Hour Sleep-Wake Disorder</span> and was granted orphan drug status by the FDA in 2010.</span></span></p>
<div>
</div>
</div>
<br />
|
| InChI | InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 |
| Reference | <br />
1:A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients. Edmonds C, Swanoski M.Consult Pharm. 2017 Mar 1;32(3):156-160. doi: 10.4140/TCP.n.2017.156. PMID: 28270270<br />
2:Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. Keating GM.CNS Drugs. 2016 May;30(5):461-8. doi: 10.1007/s40263-016-0330-y. Review. PMID: 27003694<br />
3:Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH.Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4. PMID: 26466871<br />
4:Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Leger D, Quera-Salva MA, Vecchierini MF, Ogrizek P, Perry CA, Dressman MA.Expert Opin Drug Saf. 2015;14(11):1673-85. doi: 10.1517/14740338.2015.1093112. Epub 2015 Sep 22. PMID: 26393492<br />
5:Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P.J Clin Pharmacol. 2015 Sep;55(9):1004-11. doi: 10.1002/jcph.507. Epub 2015 May 7. PMID: 25851638<br />
6:Tasimelteon for the treatment of non-24-hour sleep-wake disorder. Neubauer DN.Drugs Today (Barc). 2015 Jan;51(1):29-35. doi: 10.1358/dot.2015.51.1.2258364. Review. PMID: 25685859<br />
7:Absolute Bioavailability of Tasimelteon. Torres R, Dressman MA, Kramer WG, Baroldi P.Am J Ther. 2015 Sep-Oct;22(5):355-60. doi: 10.1097/MJT.0000000000000195. PMID: 25658956<br />
8:Tasimelteon: a selective and unique receptor binding profile. Lavedan C, Forsberg M, Gentile AJ.Neuropharmacology. 2015 Apr;91:142-7. doi: 10.1016/j.neuropharm.2014.12.004. Epub 2014 Dec 19. PMID: 25534555 Free Article<br />
9:Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. Torres R, Kramer WG, Baroldi P.J Clin Pharmacol. 2015 May;55(5):525-33. doi: 10.1002/jcph.440. Epub 2015 Feb 4. PMID: 25450415 Free PMC Article<br />
10:Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. Stahl SM.CNS Spectr. 2014 Dec;19(6):475-8. doi: 10.1017/S1092852914000637. Review. PMID: 25422900
|
